Sign in
CompletedPhase 4

GM-CSF for Reversal of immunopAralysis in pediatriC sEpsis-induced MODS Study

Key facts

Who runs it
Nationwide Children's Hospital
Where
Aurora, Columbus, Detroit, Los Angeles, Philadelphia, Pittsburgh, San Francisco, and Washington D.C., United StatesSee the 8 sites
Trial code
Status
Completed
Phase
Phase 4
People taking part
75 people enrolled
Started
5 Dec 2018
Ended
5 Dec 2023
Type of study
Interventional, 4 groups
Treatments tested
  • GM-CSF
Record updated
5 May 2026

Who can take part

Age
Up to 17 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 18 criteriaShow less

Who can take part

  • >= 40 weeks gestational age to <18 years; AND
  • Onset of >=2 new organ dysfunctions (compared to pre-sepsis baseline) as measured by the Proulx criteria; AND
  • Documented or suspected infection as the MODS inciting event

Who cannot take part

  • Renal replacement therapy at the time of screening; OR
  • Previous enrollment in the GRACE study
  • Active (or planned within 7 days) immunosuppressive treatment for oncologic, transplant, or rheumatologic disease; OR
  • Known primary immunodeficiency disorder; OR
  • Diagnosis of myeloid leukemia, myelodysplasia, or autoimmune thrombocytopenia;OR
  • Known allergy to GM-CSF; OR
  • Documented hyperferritinemia (serum ferritin >= 500 ng/ml) during current sepsis event; OR
  • Unable to collect a cumulative total of 20.5 mL of blood for this study due to research blood draw limits; OR
  • Limitation of care order at the time of screening; OR
  • Patients at high risk for brain death; OR
  • Contraindication to SQ injection (ECMO); OR
  • Burns where >5% of the total body surface area is affected; OR
  • On ECMO or anticipated to require ECMO; OR
  • Known pregnancy; OR
  • Inability to collect and ship sample for immune testing on MODS Day 2; OR

Where in United States

  • Children's Hospital of ColoradoAurora, United States
  • Nationwide Children's HospitalColumbus, United States
  • Children's Hospital of MichiganDetroit, United States
  • UCLA Mattel Children's HospitalLos Angeles, United States
  • Children's Hospital of PhiladelphiaPhiladelphia, United States
  • Children's Hospital of PittsburghPittsburgh, United States
  • Benioff Children's Hospital/UCSFSan Francisco, United States
  • Children's National Medical CenterWashington D.C., United States

About the trial

What the trial wants to find out

This study is an open-label, multi-center, interventional trial in which children with sepsis-induced MODS undergo surveillance immune function testing beginning on Day 2 of MODS. Those children who demonstrate immunoparalysis (TNF-alpha response <200 pg/ml) will receive a 7-day course of GM-CSF at a dose of 125 or 250 mcg/m2/day by either the intravenous (IV) or subcutaneous (SQ) route.

Read full original descriptionShow less

The goal of the study is to establish the dose and route of delivery that results in resolution of immunoparalysis (TNF-alpha response >=200 pg/ml) by the morning after the 3rd scheduled dose with persistent resolution of immunoparalysis on the morning after the 7th scheduled dose. Resolution of immunoparalysis in 8 out of the first 10 subjects in a study treatment arm represents a successful dose and route. The goal of this study will be achieved through the following Specific Aims:

Specific Aim 1. Establish the immunologic efficacy of GM-CSF administered by the IV and SQ routes in children with immunoparalysis in the setting of sepsis-induced MODS.

Specific Aim 2. Estimate the pharmacokinetic parameters by the IV and SQ GM-CSF administered in pediatric sepsis-induced MODS.

Specific Aim 3. Demonstrate the feasibility of screening, enrollment, drug delivery, and sample collection for a multi-center immunostimulation trial in children with sepsis-induced MODS.

The 4 groups in the trial

  • IV GM-CSF 125 mcg/m2/doseTreatment being tested

    Subjects in this arm who demonstrate immunoparalysis will receive GM-CSF by the intravenous (IV) route at a dose of 125 mcg/m2/day for 7 consecutive days.

    Treatment: GM-CSF

  • SQ GM-CSF 125 mcg/m2/doseTreatment being tested

    Subjects in this arm who demonstrate immunoparalysis will receive GM-CSF by the subcutaneous (SQ) route at a dose of 125 mcg/m2/day for 7 consecutive days.

    Treatment: GM-CSF

  • IV GM-CSF 250 mcg/m2/doseTreatment being tested

    If the IV 125 mcg/m2/dose arm is not successful in the first cohort of subjects, we will transition to 250 mcg/m2/day via the IV route for 7 consecutive days in a subsequent cohort.

    Treatment: GM-CSF

  • SQ GM-CSF 250 mcg/m2/doseTreatment being tested

    If the SQ 125 mcg/m2/dose arm is not successful in a cohort of subjects (or if the IV dose had to be escalated to 250 mcg/m2/dose), we will transition to 250 mcg/m2/day via the SQ route for 7 consecutive days in a subsequent cohort.

    Treatment: GM-CSF

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
GM-CSF for Reversal of immunopAralysis in pediatriC sEpsis-induced MODS (GRACE)
Record updated
5 May 2026